New Zealand vs Norway: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
New Zealand
0.0%
in 2024
Norway
0.0%
in 2024
New Zealand rank
167th
Norway rank
167th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- New Zealand
- Norway
How they compare
New Zealand currently reports 0.0% against 0.0% in Norway, a difference of 0.0%.
Across all 10 years both countries report, Norway has been ahead every year.
New Zealand ranks 167th and Norway ranks 167th of 246 countries.
Norway has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | New Zealand | Norway | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | Norway |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, New Zealand or Norway?
- New Zealand, at 0.0% against 0.0% in Norway as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between New Zealand and Norway?
- 0.0%, with New Zealand ahead.
- How many years of comparable data are there for New Zealand and Norway?
- 10 years are reported by both, from 2015 to 2024.
- How do New Zealand and Norway rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- New Zealand ranks 167th and Norway ranks 167th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.